EmergeTech 2025 – Chennai Edition

Astellas Acquires Iveric Bio

Naoki Okamura, President and CEO, Astellas
Naoki Okamura, President and CEO, Astellas

Astellas Pharma Inc. yesterday announced that it has successfully completed the acquisition of IVERIC bio, Inc. with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas’ wholly-owned subsidiary.

The completion of the Acquisition followed the satisfaction of all conditions, including approval by Iveric Bio’s shareholders at a special meeting of Iveric Bio’s shareholders held on July 6, 2023, US Eastern Time, and receipt of all necessary regulatory approvals. In connection with the Acquisition, shares of Iveric Bio’s common stock were delisted from NASDAQ.

“We are very pleased to welcome Iveric Bio and its highly experienced professionals in the ophthalmology field, as a member of Astellas,” said Naoki Okamura, President and CEO, Astellas. “By combining the capabilities of Astellas and Iveric Bio, we will potentially contribute to millions of patients around the world who are suffering from ophthalmologic diseases with fear of vision loss.”

Glenn P. Sblendorio, CEO, Iveric Bio
Glenn P. Sblendorio, CEO, Iveric Bio

“Today marks an exciting new chapter for Iveric Bio,” said Glenn P. Sblendorio, CEO, Iveric Bio. “We want to thank the outgoing Iveric board for their dedicated work over the years and most importantly, we greatly appreciate the support of the Iveric shareholders.”

Pravin U. Dugel, President, Iveric Bio
Pravin U. Dugel, President, Iveric Bio

“We believe that along with our colleagues at Astellas, we are well-positioned to become the leader in the development and commercialization of differentiated treatments for retinal diseases,” said Pravin U. Dugel, President, Iveric Bio. “We are excited about the opportunities that are before us as both companies combine existing strengths and prepare for the potential approval and launch of Avacincaptad Pegol for the treatment of Geographic Atrophy secondary to Age-Related Macular Degeneration, a devastating disease that leads to irreversible blindness.”

Source

Interested to read about other events in the healthcare industry? Then please read –

BVI completes acquisition of Medical Mix

ObservSMART collabs with Praesum Healthcare

XRP Healthcare Expands its Healthcare Services to the African Continent

Swisslog Healthcare to Showcase Pharmacy Automation Technology in California

(Visited 65 times, 1 visits today)

Share:

Facebook
Twitter
WhatsApp
LinkedIn

 

Comments are closed.

Social Media

Most Popular

BingX New Dual Investment Offering Sees USD 1M in User Participation (Image Courtesy: PRNewswire)
BingX New Dual Investment Offering Sees USD 1M in User Participation
Representitive Image Credit: Bitcoin p2p concept illustration on Freepik
Plume Doubles Down on New York City as Home for Real-World Asset Innovation
Yayang Ruzaldy (Co-Representative, PT Dua Saudara Nusantara), Rendy Ronaldy Bimantara (CEO, PT Dua Saudara Nusantara), Wook Lee (CEO, Edena Capital Partners), Chase S. Cho (Co-CEO, Edena Capital Partners) (Photo Courtesy: PRNewswire)
Edena announces entry into Indonesian Digital Securities Market 
MEXC Unveils "Proof of Trust" Campaign for Crypto Security, Audits, and User Protection (Image Courtesy: PRNewswire)
MEXC Unveils "Proof of Trust" Campaign for Crypto Security, Audits, and User Protection

Related Posts